U.S. health authorities have announced promising preliminary results from a landmark clinical trial. An injectable drug administered every two months offers robust protection against HIV, presenting a more convenient alternative to daily PrEP tablets.
In a May 18, 2020, press release, the National Institutes of Health (NIH) hailed cabotegravir—a potent HIV integrase inhibitor—as a potential revolution in HIV prevention. Delivered via injection, it blocks HIV from integrating into human cells, effectively safeguarding users.
Launched over three years prior, the trial spanned seven countries, including South Africa, Brazil, the United States, and Thailand. It focused on men who have sex with men and transgender women under 30—the demographic at highest risk for HIV infection.
Currently, the only approved preventive options are Truvada and Descovy, both forms of PrEP (pre-exposure prophylaxis), which reduce infection risk by 99% during unprotected sex. However, daily adherence poses a major challenge, prompting researchers to explore longer-acting solutions.
The cabotegravir trial enrolled 4,500 participants divided into two groups. One received cabotegravir injections every two months plus PrEP placebo pills; the other took daily Truvada PrEP with placebo injections. Of 50 total HIV infections, only 12 occurred in the cabotegravir group versus 38 in the PrEP group—demonstrating 69% greater efficacy. A parallel trial in women is ongoing.
In the U.S., around 200,000 people rely on PrEP for prevention. NIH experts praise cabotegravir as more effective and user-friendly, positioning it as a likely successor. This advance complements ongoing efforts toward an HIV vaccine.
